<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00514540</url>
  </required_header>
  <id_info>
    <org_study_id>2006-0097</org_study_id>
    <nct_id>NCT00514540</nct_id>
  </id_info>
  <brief_title>Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer</brief_title>
  <official_title>Phase II Study of Carboplatin Plus Docetaxel (Taxotere) in Patients With Anaplastic Prostate Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn about how effective 2 chemotherapy drugs&#xD;
      carboplatin (Paraplatin) plus docetaxel (Taxotere) in the treatment of patients with&#xD;
      anaplastic prostate cancer. Patients who continue to have advanced disease will be switched&#xD;
      to etoposide (VePesid) plus cisplatin (Platinol-AQ) to study how effective this second line&#xD;
      of chemotherapy is in the treatment of patients iwth anaplastic prostate cancer.&#xD;
&#xD;
      The side effects, characteristics of patients who respond, and overall survival will also be&#xD;
      studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Carboplatin is designed to interfere with the growth of cancer cells by stopping cell&#xD;
      division.&#xD;
&#xD;
      Docetaxel is designed to stop the growth of cancer cells, which may cause the cells to die.&#xD;
      It is believed to be weakly effective at killing blood vessels in cancer cells as well.&#xD;
&#xD;
      Etoposide is a drug that has been shown to interfere with the growth of cancer cells, which&#xD;
      may cause them to eventually die.&#xD;
&#xD;
      Cisplatin has an atom at its center that contains platinum. The platinum is supposed to&#xD;
      poison the cancer cells, which may cause them to eventually die.&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will receive carboplatin plus&#xD;
      docetaxel by a vein or central line in a vein. You will receive carboplatin over about 30&#xD;
      minutes and docetaxel over about 60 minutes. You will receive this therapy combination on Day&#xD;
      1 of each cycle of therapy (every 3-4 weeks), depending on the recovery of your bone marrow.&#xD;
      These 3-4 weeks are considered 1 cycle of therapy. This therapy combination will be given on&#xD;
      an outpatient basis. If you experience any side effects, your dose of docetaxel plus&#xD;
      carboplatin may be decreased.&#xD;
&#xD;
      You will be given dexamethasone, by a vein in your arm, by central line in a vein, or by&#xD;
      mouth, before your therapy begins with docetaxel plus carboplatin. Dexamethasone will help&#xD;
      decrease bone marrow inflammation. You will also be given a colony stimulating factor (when&#xD;
      the doctor thinks it is needed) to help maintain your white blood cell count to help decrease&#xD;
      any chance of infection. Colony stimulating factor will be given as a subcutaneous injection&#xD;
      (under the skin), at the discretion of the treating physician, during therapy.&#xD;
&#xD;
      You will have about 2-3 tablespoons of blood drawn at the beginning of each cycle of therapy&#xD;
      for routine blood tests and blood tests for cancer markers. You will be asked about any&#xD;
      medications you are currently taking.&#xD;
&#xD;
      At the end of the first 2 cycles of therapy, you will have some or all of the scans&#xD;
      (performed during the screening visit) repeated to evaluate your disease. If your disease is&#xD;
      responding well to the therapy, you will continue on docetaxel plus carboplatin for 2 more&#xD;
      cycles. In this case, you will continue receive the study combination until your doctor&#xD;
      thinks you have received the most benefit. You will then be followed with some or all of the&#xD;
      scans (performed during the screening visit) every 2 months unless your cancer progresses&#xD;
      (gets worse) or until you begin on a new therapy after your treatment has ended on this&#xD;
      study.&#xD;
&#xD;
      If you are already taking hormone therapy with an luteinizing hormone-releasing hormone&#xD;
      (LHRH) agonist (such as Lupron or Zoladex) , you will continue taking these medications. If&#xD;
      you are taking an anti-androgen drug (such as Casodex), you should stop taking it.&#xD;
&#xD;
      If your cancer is progressing after having had a maximal response, if your disease does not&#xD;
      respond after 2 courses of therapy, or if you are not able to tolerate some side effects of&#xD;
      docetaxel plus carboplatin, your chemotherapy will be switched to etoposide plus cisplatin.&#xD;
      If this is the case, etoposide plus cisplatin will be given to you by a vein in your arm or&#xD;
      central line in a vein. You will receive this therapy combination once a day (etoposide over&#xD;
      60 minutes and cisplatin over 2 hours) for the first 3 days during each cycle of therapy, and&#xD;
      then therapy will be repeated every 3 to 4 weeks.&#xD;
&#xD;
      Therapy with etoposide plus cisplatin will be continued as long as your cancer responds well&#xD;
      to this therapy and you are not experiencing any intolerable side effects. If you experience&#xD;
      any side effects, your dose of etoposide plus cisplatin may be decreased. This treatment&#xD;
      combination may be given on an inpatient basis.&#xD;
&#xD;
      You will be removed from this study if your disease gets worse or you experience any&#xD;
      intolerable side effects.&#xD;
&#xD;
      If you come off this study because you completed therapy, your disease got worse, or you&#xD;
      experienced intolerable side effects, you will have an end-of-study visit. During this visit,&#xD;
      you will have blood drawn (about 3 tablespoons) for routine tests. You will have a complete&#xD;
      physical exam, including measurement of your vital signs. You will also have your complete&#xD;
      medical history recorded and you will be asked about any medications you are currently&#xD;
      taking. You will have imaging scans to evaluate your disease (similar to those at screening)&#xD;
      if they have not been done in the last 28 days.&#xD;
&#xD;
      Once you are no longer on this study, the research staff will periodically check up on you&#xD;
      (about every 6 months). This update will consist of a phone call, an e-mail, or a review of&#xD;
      your medical and/or other records. No clinic visits or additional diagnostic studies are&#xD;
      required by the study. If contacted by phone, the call would only last a few minutes.&#xD;
&#xD;
      This is an investigational study. Carboplatin, docetaxel, etoposide, and cisplatin are all&#xD;
      commercially available and approved by the FDA. Up to 120 patients will take part in this&#xD;
      multicenter study. Up to 90 will be enrolled at MD Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Time to Progression (TTP)</measure>
    <time_frame>Baseline to evaluation at end of course 2 (up to 168 days) then every 2 months for disease progression. Follow up every 6 months and overall study period was six and half years.</time_frame>
    <description>TTP defined as time of registration on study till disease progression. Disease status evaluated at the end of course 1 (up to 84 days after day 1 of cycle 1) and at the end of course 2 (up to 168 days after day 1 of cycle 1).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response Rate of Salvage Chemotherapy With Etoposide Plus Cisplatin Following Treatment With Docetaxel Plus Carboplatin.</measure>
    <time_frame>Evaluated at the end of course 1 (up to 84 days after day 1 of cycle 1) and at the end of course 2 (up to 168 days after day 1 of cycle 1)</time_frame>
    <description>Response rate is the number of participants with response compared to total. Response defined as the absence of disease progression compared to the participant's baseline evaluation, and the time to a serious adverse event (SAE), defined as grade 3 or 4 neurotoxicity or death.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>First-Line/Second-Line Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First-Line (CD) Chemotherapy: Carboplatin area under the curve (AUC) = 5, intravenous (IV) over 30 minutes and Docetaxel 75 mg/m^2 IV over 60 minutes, Day 1. Repeated every 3 weeks.&#xD;
Second-Line (EP) Chemotherapy: Etoposide 120 mg/m^2 daily for 3 days and Cisplatin 25 mg/m^2 for 3 days with adequate intravenous hydration mannitol diuresis and supportive care (antiemetics). Repeated every 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>75 mg/m^2 IV over 60 Minutes on Day 1 of 21 day cycle.</description>
    <arm_group_label>First-Line/Second-Line Chemotherapy</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>AUC = 5 IV Over 30 Minutes On Day 1 of 21 day cycle.</description>
    <arm_group_label>First-Line/Second-Line Chemotherapy</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>120 mg/m^2 daily for 3 days of 21 day cycle.</description>
    <arm_group_label>First-Line/Second-Line Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>25 mg/m^2 for 3 days of 21 day cycle.</description>
    <arm_group_label>First-Line/Second-Line Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient must have androgen independent Stage IV prostate cancer, with anaplastic&#xD;
             features as defined by at least one of the following: a) Histologic evidence of small&#xD;
             cell(pure/mixed), locally advanced or metastatic; b) Any of the following at Dx:&#xD;
             exclusive visceral mets, predominant lytic mets, bulky ( &gt;/= 5 cm) lymphadenopathy, or&#xD;
             bulky ( &gt;/= 5 cm) high-grade (Gleason &gt;/= 8) tumor mass in the prostate/pelvis c) Low&#xD;
             prostate-specific antigen (PSA) at diagnosis (Dx) + high volume bone mets.&#xD;
&#xD;
          2. (#1 cont'd) d) Neuroendocrine markers in histology (+ Chromogranin A and/or&#xD;
             Synaptophysin) or serum (abnl high serum Chromogranin A or Bombesin) at Dx or at&#xD;
             progression plus any of the following: elevated serum lactate dehydrogenase (LDH),&#xD;
             malignant HyperCa+, or elevated serum Carcinoembryonic Antigen (CEA) in the absence of&#xD;
             other etiologies. e) Short interval (&lt; 6 months) to androgen-independent progression&#xD;
             following initiation of hormonal therapy with or without presence of neuroendocrine&#xD;
             markers.&#xD;
&#xD;
          3. Patients with small cell carcinoma on histology are not required to have received&#xD;
             prior androgen deprivation therapy (ADT). All other patients must have evidence of&#xD;
             disease progression while on ADT or an unsatisfactory response to &gt;/= 1 month of&#xD;
             castration, as defined by lack of symptom control and/or serum tumor marker response&#xD;
             of &lt; 20% (confirmed by a second value drawn on a different day).&#xD;
&#xD;
          4. Zubrod performance status of &lt;/= 2.&#xD;
&#xD;
          5. Normal EKG or, if EKG is suggestive of cardiomyopathy, patient has a resting Left&#xD;
             Ventricular Ejection Fraction (LEVF) &gt;/= 50% within 4 months.&#xD;
&#xD;
          6. Patient has all of the following pretreatment laboratory data within 14 days before&#xD;
             registration: • Absolute neutrophil count (ANC) &gt;=1,500/mm^3.(unless due to bone&#xD;
             marrow infiltration by tumor, in which case ANC &gt;/= 500/mm^3 are allowed). • Platelets&#xD;
             &gt;=100,000/mm^3 (unless due to bone marrow infiltration by tumor, in which case&#xD;
             platelets &gt;/= 20,000/mm^3 are allowed)&#xD;
&#xD;
          7. (#7 cont'd) • Total bilirubin &lt;/= 2 mg/dl; if greater, conjugated bilirubin should be&#xD;
             &lt;= 1.0 mg/dL, • serum glutamate pyruvate transaminase (SGPT) (ALT) and/or serum&#xD;
             glutamate oxaloacetate transaminase (SGOT) (AST) &lt;/= 4 times the upper limit of normal&#xD;
             (ULN). • Creatinine clearance &gt;/= 40 (either measured or calculated by Cockcroft&#xD;
             formula) • Castrate levels of serum testosterone (&lt;/= 50ng/mL) if no small cell&#xD;
             elements on histology. (If small cell, testosterone &gt; 50ng/mL)&#xD;
&#xD;
          8. Patient has given voluntary written informed consent before performance of any&#xD;
             study-related procedure not part of standard medical care.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Immunotherapy or chemotherapy within four weeks (nitrosoureas within six weeks) of&#xD;
             registration.&#xD;
&#xD;
          2. 2 or more prior chemotherapy regimens (ketoconazole, aminoglutethimide or dutasteride&#xD;
             do not count as chemotherapy for this trial).&#xD;
&#xD;
          3. Prior Platinum, Etoposide, or Taxane-based therapy that was completed less than 6&#xD;
             months from registration.&#xD;
&#xD;
          4. Samarium-153 within four weeks of registration, or Strontium-89 within 12 weeks of&#xD;
             registration. Patients who have received 2 or more doses of bone-seeking radioisotopes&#xD;
             are not eligible.&#xD;
&#xD;
          5. Patient has not recovered from all serious toxic effects of previous chemotherapy,&#xD;
             radiation or antibody therapy, or from previous major surgery.&#xD;
&#xD;
          6. Patients with symptomatic and untreated brain metastases or central nervous system&#xD;
             disease will be excluded. Patients with untreated, asymptomatic brain metastasis (not&#xD;
             requiring corticosteroid treatment for control of central nervous system (CNS)&#xD;
             symptoms) may be eligible, at the discretion of the MDACC Principal Investigator.&#xD;
             Patients with treated brain metastases are eligible.&#xD;
&#xD;
          7. Patient with significant atherosclerotic disease, as defined by: a) myocardial&#xD;
             infarction within six months of enrollment. Current uncontrolled/unstable angina&#xD;
             pectoris or electrocardiographic evidence of acute ischemia b) clinically significant&#xD;
             ventricular arrhythmias c) symptomatic congestive heart failure (NYHA Class III)&#xD;
&#xD;
          8. Patient has &gt;= Grade 2 peripheral neuropathy.&#xD;
&#xD;
          9. Patient has renal insufficiency with cranial cruciate ligament (CrCL) &lt; 40 ml/min with&#xD;
             non-correctable etiologies.&#xD;
&#xD;
         10. Patient has an uncontrolled intercurrent illness (e.g., active infection).&#xD;
&#xD;
         11. Patient has another serious medical or psychiatric illness that could, in the&#xD;
             investigator's opinion, potentially interfere with the patient's ability to provide&#xD;
             informed consent or with the completion of treatment according to this protocol.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana M. Aparicio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California-San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center website</description>
  </link>
  <results_reference>
    <citation>Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013 Jul 1;19(13):3621-30. doi: 10.1158/1078-0432.CCR-12-3791. Epub 2013 May 6.</citation>
    <PMID>23649003</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 9, 2007</study_first_submitted>
  <study_first_submitted_qc>August 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2007</study_first_posted>
  <results_first_submitted>April 30, 2014</results_first_submitted>
  <results_first_submitted_qc>August 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 1, 2020</results_first_posted>
  <last_update_submitted>August 17, 2020</last_update_submitted>
  <last_update_submitted_qc>August 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Anaplastic Prostate Cancer</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Taxotere</keyword>
  <keyword>Paraplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All participants were enrolled between June 2006 and October 2010 at The University of Texas (UT) MD Anderson Cancer Center (MDACC).</recruitment_details>
      <pre_assignment_details>Of the 121 participants enrolled, seven were ineligible and excluded. Another participant was eligible but withdrew before treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Chemotherapy First-Line Chemo (CD) + Second-Line (EP)</title>
          <description>First-Line (CD) Chemotherapy: Carboplatin area under the curve (AUC) = 5, intravenous (IV) over 30 minutes and Docetaxel 75 mg/m^2 IV over 60 minutes, Day 1. Repeated every 3 weeks. Colony stimulating factors given prophylactically per National Comprehensive Cancer Network (NCCN) guidelines.&#xD;
Second-Line (EP) Chemotherapy: Etoposide 120 mg/m^2 daily for 3 days and Cisplatin 25 mg/m^2 for 3 days with adequate intravenous hydration mannitol diuresis and supportive care (antiemetics). Repeated every 3 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First-Line Chemo</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second-Line</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician/Patient Decision</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Eligibile population treated.</population>
      <group_list>
        <group group_id="B1">
          <title>First-Line CD + Second-Line EP</title>
          <description>First-Line (CD) Chemotherapy: Carboplatin area under the curve (AUC) = 5, intravenous (IV) over 30 minutes and Docetaxel 75 mg/m^2 IV over 60 minutes, Day 1. Repeated every 3 weeks. Colony stimulating factors given prophylactically per National Comprehensive Cancer Network (NCCN) guidelines.&#xD;
Second-Line (EP) Chemotherapy: Etoposide 120 mg/m^2 daily for 3 days and Cisplatin 25 mg/m^2 for 3 days with adequate intravenous hydration mannitol diuresis and supportive care (antiemetics). Repeated every 3 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="113"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" lower_limit="39" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Time to Progression (TTP)</title>
        <description>TTP defined as time of registration on study till disease progression. Disease status evaluated at the end of course 1 (up to 84 days after day 1 of cycle 1) and at the end of course 2 (up to 168 days after day 1 of cycle 1).</description>
        <time_frame>Baseline to evaluation at end of course 2 (up to 168 days) then every 2 months for disease progression. Follow up every 6 months and overall study period was six and half years.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>First-Line: Carboplatin + Docetaxel</title>
            <description>Carboplatin area under the curve (AUC) = 5, intravenous (IV) over 30 minutes and Docetaxel 75 mg/m^2 IV over 60 minutes, Day 1 repeated every 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Second-Line: Etoposide + Cisplatin</title>
            <description>Etoposide 120 mg/m^2 daily for 3 days and Cisplatin 25 mg/m^2 for 3 days with adequate intravenous hydration mannitol diuresis and supportive care (antiemetics). Repeated every 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Progression (TTP)</title>
          <description>TTP defined as time of registration on study till disease progression. Disease status evaluated at the end of course 1 (up to 84 days after day 1 of cycle 1) and at the end of course 2 (up to 168 days after day 1 of cycle 1).</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="4.2" upper_limit="6.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="1.6" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Disease status evaluated at the end of course 1 &amp; the end of course 2. Primary outcomes are response, defined as the absence of disease progression, and the time to a serious adverse event (SAE), defined as grade 3 or 4 neurotoxicity or death. Bayesian probability model &amp; decision rules used to monitor patient outcomes.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt; 0.005</p_value>
            <p_value_desc>Stoppage of trial early if 1) probability of response with the frontline treatment DC in the 1st 2 courses is unacceptably low compared to a target of 30% Pr(p1*p2 &gt; .30|data) &lt; 0.005, or 2) risk of a SAE is unacceptably high Pr(m &gt; m* |data) &lt; 0.001</p_value_desc>
            <method>Bayesian probability model</method>
            <method_desc>Operating Characteristics of futility monitoring rule 1 &amp; safety monitoring rule 2 applied simultaneously for frontline treatment DC in courses 1 &amp; 2.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Response Rate of Salvage Chemotherapy With Etoposide Plus Cisplatin Following Treatment With Docetaxel Plus Carboplatin.</title>
        <description>Response rate is the number of participants with response compared to total. Response defined as the absence of disease progression compared to the participant's baseline evaluation, and the time to a serious adverse event (SAE), defined as grade 3 or 4 neurotoxicity or death.</description>
        <time_frame>Evaluated at the end of course 1 (up to 84 days after day 1 of cycle 1) and at the end of course 2 (up to 168 days after day 1 of cycle 1)</time_frame>
        <population>74 of the 105 participants received second-line EP on study; the remainder withdrew from the study at their physician's or their own request. 2 participants died after course 1 of EP.</population>
        <group_list>
          <group group_id="O1">
            <title>Second-Line: EP, Course 1</title>
            <description>Etoposide 120 mg/m^2 daily for 3 days and Cisplatin 25 mg/m^2 for 3 days with adequate intravenous hydration mannitol diuresis and supportive care (antiemetics). Repeated every 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Second-Line: EP, Course 2</title>
            <description>Etoposide 120 mg/m^2 daily for 3 days and Cisplatin 25 mg/m^2 for 3 days with adequate intravenous hydration mannitol diuresis and supportive care (antiemetics). Repeated every 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate of Salvage Chemotherapy With Etoposide Plus Cisplatin Following Treatment With Docetaxel Plus Carboplatin.</title>
          <description>Response rate is the number of participants with response compared to total. Response defined as the absence of disease progression compared to the participant's baseline evaluation, and the time to a serious adverse event (SAE), defined as grade 3 or 4 neurotoxicity or death.</description>
          <population>74 of the 105 participants received second-line EP on study; the remainder withdrew from the study at their physician's or their own request. 2 participants died after course 1 of EP.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>One therapy course consists of two (2) cycles, each cycle is defined as 21 days. Safety stopping rule assessed at the end of one course Docetaxel + Carboplatin and at the end of one course Etoposide + Cisplatin. Toxicity data collected for all cycles.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>First-Line: Carboplatin + Docetaxel</title>
          <description>Carboplatin area under the curve (AUC) = 5, intravenous (IV) over 30 minutes and Docetaxel 75 mg/m2 IV over 60 minutes, Day 1 repeated every 3 weeks</description>
        </group>
        <group group_id="E2">
          <title>Second Line: Etoposide + Cisplatin</title>
          <description>Etoposide 120 mg/m2 daily for 3 days and Cisplatin 25 mg/m2 for 3 days with adequate intravenous hydration mannitol diuresis and supportive care (antiemetics), Repeated every 3 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Edema: Limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Neutrophils/Granulocytes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Vasovagal episode</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="113"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="113"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Lung pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="113"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Upper airway infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Bladder infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS cerebrovascular ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Disseminated Intravascular Coagulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrophils/Granulocytes</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" events="129" subjects_affected="62" subjects_at_risk="113"/>
                <counts group_id="E2" events="36" subjects_affected="22" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="9" subjects_at_risk="113"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <description>Head and neck, limbs, trunk/genital, viscera</description>
                <counts group_id="E1" events="34" subjects_affected="18" subjects_at_risk="113"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Leukocytes (Total WBC)</sub_title>
                <counts group_id="E1" events="204" subjects_affected="70" subjects_at_risk="113"/>
                <counts group_id="E2" events="60" subjects_affected="27" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Neutrophils/Granulocytes</sub_title>
                <counts group_id="E1" events="129" subjects_affected="62" subjects_at_risk="113"/>
                <counts group_id="E2" events="96" subjects_affected="22" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="124" subjects_affected="53" subjects_at_risk="113"/>
                <counts group_id="E2" events="124" subjects_affected="42" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Watery Eye</sub_title>
                <counts group_id="E1" events="45" subjects_affected="26" subjects_at_risk="113"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="8" subjects_at_risk="113"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="113"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="216" subjects_affected="75" subjects_at_risk="113"/>
                <counts group_id="E2" events="64" subjects_affected="34" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="6" subjects_at_risk="113"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Vomitting</sub_title>
                <counts group_id="E1" events="97" subjects_affected="33" subjects_at_risk="113"/>
                <counts group_id="E2" events="24" subjects_affected="13" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="139" subjects_affected="56" subjects_at_risk="113"/>
                <counts group_id="E2" events="31" subjects_affected="29" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="34" subjects_affected="17" subjects_at_risk="113"/>
                <counts group_id="E2" events="15" subjects_affected="9" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (Asthenia, Lethargy, Malaise)</sub_title>
                <counts group_id="E1" events="359" subjects_affected="99" subjects_at_risk="113"/>
                <counts group_id="E2" events="125" subjects_affected="44" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="113"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="23" subjects_affected="17" subjects_at_risk="113"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with normal ANC</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="113"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="45" subjects_affected="27" subjects_at_risk="113"/>
                <counts group_id="E2" events="27" subjects_affected="17" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>ALT elevated</sub_title>
                <counts group_id="E1" events="25" subjects_affected="15" subjects_at_risk="113"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>AST elevated</sub_title>
                <counts group_id="E1" events="42" subjects_affected="28" subjects_at_risk="113"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="36" subjects_affected="10" subjects_at_risk="113"/>
                <counts group_id="E2" events="30" subjects_affected="15" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="17" subjects_affected="12" subjects_at_risk="113"/>
                <counts group_id="E2" events="18" subjects_affected="13" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="211" subjects_affected="76" subjects_at_risk="113"/>
                <counts group_id="E2" events="139" subjects_affected="47" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="67" subjects_affected="38" subjects_at_risk="113"/>
                <counts group_id="E2" events="66" subjects_affected="35" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="113"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="30" subjects_affected="21" subjects_at_risk="113"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="45" subjects_affected="26" subjects_at_risk="113"/>
                <counts group_id="E2" events="42" subjects_affected="25" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="113"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy: Sensory</sub_title>
                <counts group_id="E1" events="79" subjects_affected="45" subjects_at_risk="113"/>
                <counts group_id="E2" events="23" subjects_affected="16" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="68" subjects_affected="42" subjects_at_risk="113"/>
                <counts group_id="E2" events="24" subjects_affected="21" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hair Loss/Alopecia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="113"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Injection Site Reaction/Extravasation Changes</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="113"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Nail Changes</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="113"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lisa Pruitt, Quality Assurance Specialist</name_or_title>
      <organization>University of Texas MD Anderson Cancer Center</organization>
      <phone>713-792-0411</phone>
      <email>LPruitt@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

